Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 10, October, p. 1425–1428

doi: 10.17219/acem/104537

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Hypertension and chronic kidney disease is highly prevalent in elderly patients with colorectal cancer undergoing primary surgery

Leszek Kozłowski1,A,B,C,D,E,F, Klaudia Kozłowska2,B,E,F, Jolanta Małyszko3,A,C,D,E,F

1 Department of Oncological Surgery, Cancer Center, Białystok, Poland

2 2nd Department of Nephrology, Medical University of Bialystok, Poland

3 Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Poland

Abstract

Background. Colorectal cancer (CRC) is a common and lethal disease. Hypertension is the most commonly reported comorbidity among cancer patients. Data on its incidence and prevalence is very scarce.
Objectives. The aim of the study was to evaluate the prevalence of hypertension and chronic kidney disease (CKD) in a cohort of 100 consecutive patients with CRC undergoing primary surgical treatment.
Material and Methods. The pilot study included 100 consecutive patients with CRC undergoing primary surgery with curative intent within 1 year in the Department of Oncological Surgery in Białystok, Poland. No neoadjuvant therapy was administered before the surgery.
Results. The prevalence of hypertension was 62% among the patients studied. Sixty-five percent of the patients were older than 65 years and hypertension was present in 78% of these elderly patients. The prevalence of CKD was 15%, while that of diabetes was 23%. All CKD patients were older than 65 years of age. The hypertensive patients were more likely to be older and anemic with higher serum fibrinogen, which reflects a general inflammatory state. Elderly hypertensive patients had significantly higher creatinine levels, lower estimated glomerular filtration rate (eGFR) levels (p < 0.001) and lower platelet counts.
Conclusion. It is of the utmost importance for oncology patients to have any hypertension diagnosed and treated appropriately in order to prevent complications so they may continue their therapy with the least interruption or discontinuation of treatment and to ensure the best possible outcomes.

Key words

surgery, colorectal cancer, hypertension, chronic kidney disease, elderly

References (19)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
  2. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872–877.
  3. Herrmann J, Yang EH, Iliescu CA, et al. Vascular toxicities of cancer therapies: The old and the new – an evolving avenue. Circulation. 2016;133(13):1272–1289.
  4. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl (2011). 2013;3(1):1–163.
  5. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
  6. Fraeman KH, Nordstrom BL, Luo W, Landis SH, Shantakumar S. Incidence of new-onset hypertension in cancer patients: A retrospective cohort study. Int J Hypertens. 2013;2013:379252.
  7. Kumar S, Burney IA, Zahid KF, et al. Colorectal cancer patient characteristics, treatment and survival in Oman: A single center study. Asian Pac J Cancer Prev. 2015;16(12):4853–4858.
  8. Othman NH, Zin AA. Association of colorectal carcinoma with metabolic diseases: Experience with 138 cases from Kelantan, Malaysia. Asian Pac J Cancer Prev. 2008;9(4):747–751.
  9. Ahmadi A, Mobasheri M, Hashemi-Nazari SS, Baradaran A, Choobini ZM. Prevalence of hypertension and type 2 diabetes mellitus in patients with colorectal cancer and their median survival time: A cohort study. J Res Med Sci. 2014;19(9):850–854.
  10. Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: An updated systematic review and comparative meta-analysis. Crit Rev Oncol Hematol. 2014;92(3):194–207.
  11. Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev. 2017;53:120–127.
  12. Falchook GS, Wheler JJ, Naing A, et al. Dual antiangiogenic inhibition: A phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs. 2015;33(1):215–224.
  13. Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: Lessons from the IRMA study group. Semin Nephrol. 2010;30(6):548–556. doi:10.1016/j.semnephrol.2010.09.003
  14. Dogan E, Izmirli M, Ceylan K, et al. Incidence of renal insufficiency in cancer patients. Adv Ther. 2005;22(4):357–362.
  15. Launay-Vacher V, Izzedine H, Rey JB, et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit. 2004;10:CR209–212.
  16. Janus N, Launay-Vacher V, Byloos E, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103(12):1815–1821.
  17. Na SY, Sung JY, Chang JH, et al. Chronic kidney disease in cancer patients: An independent predictor of cancer-specific mortality. Am J Nephrol. 2011;33(2):121–130.
  18. Małyszko J, Kozłowski L, Kozłowska K, Małyszko M, Małyszko J. Cancer and the kidney: Dangerous liaisons or price paid for the progress in medicine? Oncotarget. 2017;8(39):66601–66619.
  19. Małyszko J, Małyszko M, Kozłowski L, Kozłowska K, Małyszko J. Hypertension in malignancy: An underappreciated problem. Oncotarget. 2018;9(29):20855–20871.
© Wroclaw Medical University